Pancreatic cancer is the 11th commonest cancer in the UK, with around 7,800 new diagnosed cases each year (see CRUK CancerStatsRisk factors include age, family history, mutations in the BRCA2 gene, smoking, fatty and sugary diet, obesity and lack of physical activity. It is one of the least treata

read more>>

NEW YORK -- ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) today announced the initiation of the pivotal Phase III clinical trial for palifosfamide (ZymafosTM) in patients with front-line metastatic soft tissue sarcomaThe study, called PICASSO 3, is an international, randomized, double-blinded, placebo-co

read more>>

CHAPEL HILL, NC -- Pancreatic cancer is one of the most challenging tumors to treatIdentifying patients who have more aggressive disease could better inform treatment decisions and predict survival prognosis. A new finding from scientists at UNC Lineberger Comprehensive Cancer Center may helpThe

read more>>

There’s nothing worse for parents than seeing their children sufferBut what do parents do when doctors tell them there is nothing that can help make your sick child betterIn October 2007, Chris and Hugh Hempel, of Reno, Nevada, learned that their twin daughters, Addison and Cassidy, have an

read more>>

FRANKFURT -- t2cure GmbH, a biopharmaceutical company developing and marketing stem cell-based regenerative therapies, announced today that the FDA has granted orphan drug designation to t2c001 for the treatment of Buerger's DiseaseThe Company also announced that in a concurrent application in Eur

read more>>

Biovest International, Inc. (Other OTC:BVTI) today announced at the Active Immunotherapeutics Forum in Barcelona, Spain, that the Company is targeting mantle cell lymphoma, in addition to follicular lymphoma, as a next indication for its personalized cancer vaccine, BiovaxID®At the conference,

read more>>

Paris (France) and Laguna Niguel (CA, USA) -- Ipsen (Euronext : FR0010259150; IPN) and Inspiration Biopharmaceuticals, Inc. (Inspiration) announced today that the Committee for Orphan Medicinal Products of the European Medicines Agency has issued a positive opinion on the granting of orphan drug F

read more>>

TUSTIN, CA -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing innovative monoclonal antibodies for the treatment of cancer and viral infections, today will present tumor response and progression-free survival data from three clinical Phase II A

read more>>

PRINCETON, N.J. -- Celator Pharmaceuticals today announced that a subset analysis of data from its Phase 2 study in newly diagnosed acute myeloid leukemia (AML) demonstrates that CPX-351 (Cytarabine:Daunorubicin) Liposome Injection can induce complete remissions in patients following the failure of

read more>>

CHICAGO -- NewLink Genetics Corporation today announced positive Phase 2 clinical trial data of its HyperAcute®-Pancreas cancer immunotherapy combined with standard adjuvant chemotherapy in patients with surgically resectable pancreatic cancerThe study results suggest a potentially longer dise

read more>>